| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10962995 | Vaccine | 2016 | 11 Pages |
Abstract
The vaccine effectiveness of PPV23 in preventing IPD and all-cause CAP was consistent with past systematic reviews and similar to the estimates that were reported in the CAPiTA trial evaluating the vaccine effectiveness of PCV13. Consistent benefits were also reported across ecological studies and reports of surveillance data for the general population 50 years and older. The results suggests that the current practice of vaccinating the adults 65 years of age and older with PPV23 would have similar benefits to PCV13 in preventing potential cases of all-serotype IPD and all-cause CAP.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Hannah Kraicer-Melamed, Shauna O'Donnell, Caroline Quach,